Skip to main content
SAMSUNG PHARMACEUTICAL.CO.,Ltd. logo

SAMSUNG PHARMACEUTICAL.CO.,Ltd. — Investor Relations & Filings

Ticker · 001360 ISIN · KR7001360007 KO Manufacturing
Open in API
Filings indexed 196 across all filing types
Latest filing 2025-03-12 Proxy Solicitation & In…
Country KR South Korea
Listing KO 001360

About SAMSUNG PHARMACEUTICAL.CO.,Ltd.

http://www.sspharm.com/

Samsung Pharmaceutical Co., Ltd. is a company engaged in the research, development, manufacturing, and sale of pharmaceutical products. Its portfolio includes a range of medications, such as antibiotics and liver treatments, with a research focus on therapeutic areas like neoplasms. In addition to its core pharmaceutical operations, the company is also involved in the bio business and the sale of health foods.

Recent filings

Filing Released Lang Actions
의결권대리행사권유참고서류
Proxy Solicitation & Information Statement Classification · 100% confidence The document is titled '의결권대리행사권유참고서류' (Reference Document for Solicitation of Proxy), which is a standard regulatory filing in South Korea (DART system) used by companies to solicit proxies from shareholders for an upcoming Annual General Meeting (AGM). It contains the agenda, director candidate information, and financial statements for the meeting. This falls under the category of Proxy Solicitation & Information Statement.
2025-03-12 Korean
주주총회집중일개최사유신고
AGM Information Classification · 98% confidence The document is a formal regulatory filing submitted to the KRX (Korea Exchange) regarding the scheduling of a General Meeting of Shareholders on a 'concentrated date'. It explains the company's inability to avoid the concentrated date due to audit and closing schedules. Since this is a regulatory disclosure regarding meeting logistics and compliance with the 'Shareholder Meeting Dispersion Voluntary Compliance Program' rather than the meeting materials themselves or a proxy statement, it falls under the general regulatory filing category.
2025-03-12 Korean
매출액또는손익구조30%(대규모법인은15%)이상변경
Earnings Release Classification · 100% confidence The document is a regulatory filing from Samsung Pharmaceutical regarding a significant change (30% or more) in sales or profit/loss structure. It provides preliminary financial data (revenue, operating profit, net income) for the current fiscal year compared to the previous year. This type of disclosure is a standard regulatory requirement in the Korean market (KRX) for listed companies to announce material financial changes before the final audit report is filed. It fits the 'Earnings Release' (ER) category as it provides the initial announcement of financial results highlights. FY 2024
2025-02-10 Korean
주식등의대량보유상황보고서(일반)
Major Shareholding Notification Classification · 100% confidence The document is a 'Report of Large Shareholding' (주식등의 대량보유상황보고서) filed with the Financial Supervisory Service (FSS) in South Korea. It details the shareholding status of GemVax & KAEL in Samsung Pharmaceutical, specifically noting a change in status due to a stock collateral agreement (주식담보계약 체결). This type of filing is a standard regulatory disclosure regarding significant ownership thresholds and changes in control/collateral, which falls under the 'Major Shareholding Notification' category.
2024-12-24 Korean
분기보고서 (2024.09)
Interim / Quarterly Report Classification · 100% confidence The document is a '분기보고서' (Quarterly Report) for Samsung Pharm, covering the period from January 1, 2024, to September 30, 2024. It contains detailed financial and operational information, including company overview, business activities, capital changes, and production data. As it is a comprehensive financial report for a period shorter than a full fiscal year, it is classified as an Interim/Quarterly Report (IR). 9M 2024
2024-11-14 Korean
반기보고서 (2024.06)
Interim / Quarterly Report Classification · 100% confidence The document is a '반기보고서' (Semi-annual Report) for Samsung Pharm, covering the period from January 1, 2024, to June 30, 2024. It contains detailed financial information, business operations, management discussions, and corporate governance data. As it is a comprehensive financial report for a period shorter than a full fiscal year, it falls under the 'Interim / Quarterly Report' category. H1 2024
2024-08-14 Korean

Browse filings by year

9 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.